Answers are grounded in this paper and cite their sources.
Randomized trial compares safety and tolerability of GTX-104 and oral nimodipine in patients with aSAH, indicating potential treatment advantages.
To conduct a randomized, open label, blinded endpoint study of GTX-104 (intravenous [IV] nimodipine) compared with oral nimodipine in patients with aSAH.
No takes yet. Share an insight, caveat, or question.
Macdonald et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: